Personalizing CAR T: Making the Right Call for Each Patient

March 24, 2025

By Krish Patel, MD
Saurabh Dahiya, MD, FACP

Opinion

Video

Panelists discuss how patient-specific characteristics in diffuse large B-cell lymphoma significantly impact chimeric antigen receptor T-cell (CAR T) therapy outcomes, suggesting that standardized treatment algorithms may need refinement. Factors like tumor biology, immune status, and genetic profiles could help optimize therapeutic selection and sequencing.

EP: 1.DLBCL in Focus: Transforming Outcomes With CAR T Therapy

EP: 2.Beyond Salvage: When to Move to CAR T in Relapsed DLBCL

EP: 3.Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL

EP: 4.TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL

EP: 5.CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management

EP: 6.Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection

Now Viewing

EP: 7.Personalizing CAR T: Making the Right Call for Each Patient

EP: 8.Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL

EP: 9.Transplant-Eligible, CAR T Considered: How Do We Decide?

EP: 10.CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease

EP: 11.The Future of DLBCL: Innovations in Therapy and Patient Care

Video content above is prompted by the following:

In the landscape of CAR T therapies for diffuse large B-cell lymphoma, how might patient-specific profiles challenge our current narratives about therapeutic selection?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!